View all Clinical Vignettes CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These activites are not approved for AMA PRA Category 1 Credit™.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie, Astellas, AstraZeneca, Celgene Corporation, Genentech, Genomic Health, Inc., Eisai, Inc., Incyte, Lilly, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., and Pfizer.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.


34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™ PER Pulse™ Recap

PER Pulse Recap

PER Pulse™ Recap


1 of 3
PER Pulse™ Recap

34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Seriesis a series of short video interviews with faculty from the live 34th Annual Miami Breast Cancer Conference®, who address a variety of questions via discussion of clinical vignettes that were presented at the conference. The online activity features discussion on the following:

  • Neoadjuvant therapy for early-stage, HER2-positive breast cancer, by Debu Tripathy, MD
  • Immunotherapy in breast cancer, by Elizabeth Mittendorf, MD, PhD

Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This first of 3 PER Pulse™ Recaps summarizing the online program focuses on interviews with Dr. Tripathy, during which he discussed:

  • His approach toward neoadjuvant therapy and follow-up for a 57-year-old female who was diagnosed with a grade II infiltrating ductal, HER2-positive breast cancer (clinical size = 3.8 cm).
  • Key components of neoadjuvant therapy response evaluation, including examination at every cycle of chemotherapy to detect progression and pathologic assessment at the time of surgery (eg, with residual cancer burden calculator)
  • Factors that influence degree of response to neoadjuvant therapy and how it translates into conversion from mastectomy to breast-conserving surgery eligibility, including tumor location, body type, size of breast, and patient preference
  • His perspective on data showing increased rates of pathologic complete response (pCR), but not survival, when lapatinib was added to neoadjuvant trastuzumab chemotherapy
  • Clinical questions being addressed by the KATHERINE trial of adding T-DM1 to adjuvant therapy to reduce risk of recurrence for patients who did not achieve pCR after standard neoadjuvant therapy

2 of 3
PER Pulse™ Recap

34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Seriesis a series of short video interviews with faculty from the live 34th Annual Miami Breast Cancer Conference®, who address a variety of questions via discussion of clinical vignettes that were presented at the conference. The online activity features discussion on the following:

  • Neoadjuvant therapy for early-stage, HER2-positive breast cancer, by Debu Tripathy, MD
  • Immunotherapy in breast cancer, by Elizabeth Mittendorf, MD, PhD

Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This second of 3 PER Pulse™ Recaps summarizing the online program focuses on interviews with Dr. Mittendorf, during which she discussed:

  • Her approach toward discussing the status of immunotherapy with a 47-year-old female patient with metastatic, triple-negative breast cancer, who has no family history of breast or ovarian cancer and no evidence of deleterious mutations by breast cancer susceptibility gene panel testing
  • Recent data on the immunogenicity of breast cancer that provide rationale for the use of immunotherapy
  • Strategies being investigated to augment the immunogenicity/T-cell infiltrate in breast cancer

3 of 3
PER Pulse™ Recap

34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Seriesis a series of short video interviews with faculty from the live 34th Annual Miami Breast Cancer Conference®, who address a variety of questions via discussion of clinical vignettes that were presented at the conference. The online activity features discussion on the following:

  • Neoadjuvant therapy for early-stage, HER2-positive breast cancer, by Debu Tripathy, MD
  • Immunotherapy in breast cancer, by Elizabeth Mittendorf, MD, PhD

Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspective and guidance on issues important to community-based physicians.

This third of 3 PER Pulse™ Recaps summarizing the online program focuses on interviews with Dr. Mittendorf, during which she discussed:

  • Data from phase I trials of checkpoint inhibitor therapy for advanced, triple-negative breast cancer
  • How outcomes observed in trials of checkpoint inhibitors for breast cancer compare with those observed for other solid tumor types
  • Progress made toward identifying patients with breast cancer who are most likely to benefit from checkpoint inhibitor therapy
  • Rationale for using checkpoint inhibition in combination with other therapeutics




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
2627282930
Filter By